SYNGENE

It was incorporated as Syngene International Private Limited as on November 18, 1993, at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. According to a special resolution of the shareholders dated March 26, 2007, the Company was being converted into a public limited company, and the company name was changed to Syngene International Limited. Also, a fresh certificate of incorporation consequent upon conversion to the public limited company was issued as on April 19, 2007. It was also promoted by Kiran Mazumdar Shaw, who is a promoter of Biocon. On March 30, 2002, 99.9% of the Equity Shares of the Company were being transferred to Biocon, and as a result, it became the subsidiary of Biocon. It has also since been the Promoter of the Company. Also, the details of changes in the registered office of the Company are given below: From 20th KM, Hosur Road, Electronics City P.O, Bengaluru 560 100, Karnataka, India to Biocon Special Economic Zone, Biocon Park, Plot No. 2 and 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bengaluru 560 099, Karnataka, India.

Some of the Milestones:

1994: It initiated operations as a CRO with services in chemistry and biology.
1998: It granted 100% Export Oriented Unit (EOU) status by the Government of India.
1999: Its first operational expansion in R&D by way of expansion of lab space to over 23,000 sq. Ft.
2000: Also, CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
2001: It forayed into chemical development with a dedicated manufacturing facility.
2003: It moved to Biocon Park, a 90-acre biopharmaceutical SEZ with the operations spread over 65,000 sq. Ft.
2007:
Both Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D center.
The expansion of research facilities located at Biocon SEZ to 148,000 sq. Ft.
It crossed an annual turnover of over `1,000 million in Financial Year 2007.
2009:
Both Dupont Crop Protection and the Company extended a partnership for R&D services.
The expansion of manufacturing services with a new plant which is cGMP compliant.
It initiated operations in safety assessment and large molecules development services.
2010:
Also, the acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services, FDA.
It initiated operations in formulation development.
2011: Both Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer.
2012:
Both Abbott and the Company collaborated to establish Abbott's nutrition research and development center in India and the second R&D center.
It received the certification of the clinical facilities by ANVISA.
It acquired a 100% stake in Clinigene International Limited from Biocon.
2013:
It crossed an annual turnover of over INR 5,000 million in Financial Year 2013.
Also, the Baxter International Inc. collaborated with the Company to establish the ‘Baxter Global Research Center,’ the third dedicated R&D center.
The acceptance of the control testing laboratory by the Department of Health & Human Services, FDA.
2014:
Both Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D center till 2020.
The acceptance of the API manufacturing facility by the Department of Health & Human Services, FDA.
It also established a 75,000 sq.ft center to provide stability and analytical services.
2015: Also, the CIL was amalgamated with the Company.

Some of the Achievements:

2009:
It received Bangalore Bio, Bio Excellence Award, in Biotech Services Sector.
It won the Best BioServices Company of the year from Biospectrum.
2012:
It received ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
It received AAALAC accreditation for conforming to the “Guide for the Care and Use of Laboratory Animals and the Committee for Control & Supervision of the Experiments on Animals guidelines.”
2013:
It received Bioservices - ABLE Tenth Anniversary Award for the outstanding contribution to Bioservices.
It received Diamond Sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology.
2014:
It received ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
It received BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals.
It received a Silver EDGE Award.
It received the EHS best practices award by CII.
It received SAP Ace Award for special recognition for complex SAP implementation.
2015:
Also, the accreditation by the College of American Pathologists concerning their laboratory accreditation program.
It received Bangalore India Bio - Bio Excellence Award for an outstanding contribution to the Biotech services sector.
It received ISO 15189:2007 in the field of medical testing.
2017:
Both Herbalife Nutrition Partners with Syngene to Establish Nutrition Research and Development Lab in India.
The "Syngene International Announces Broadening of Research Collaboration with Amgen Inc." and expands the Dedicated R&D Center.
Both "Bristol-Myers Squibb and Syngene International Expand for an Ongoing Research Collaboration."

SYNGENE INTERNATIONAL Share Price Chart